title: [Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
abstract: The aim of the study was to optimize psychopharmacotherapy in a big psychiatric hospital. It was conducted in Moscow Alekseev psychiatric hospital No 1, using a method of comparison of standard psychotropic treatment and medication strategy suggested by the expert group. An analysis of the treatment of 966 patients with different mental disorders revealed that 78.3% were in need of neuroleptic assignment that was in line with routine practice. The expert's conclusions were postulated as follows: a need in phenothyazines is significantly lower than that observed in practice. Xantens and tyoxantens (chlorprothixene, flupentixol, zuclopenthixol, zuclopenthixol decanoate, zuclopenthixol acetate), benzamides (sulpiride) and such atypical antipsychotics as risperidone, olanzapine and quentiapine are underused in the treatment. Comparing to usual practice, more patients (35.8%) need antidepressants treatment. Thymoleptics should be assigned in greater daily doses. Selective inhibitors of serotonin reuptake (paroxetine, fluoxetine, citalopram, sertraline), reversible MAO A inhibitors (pyrazidolum), "double-action" drugs (mirtazapine, milnacipran) are recommended for wider usage. Less patients (33.4%) are in need of tranquilizers, though a number of medications used is consistent with a recommended one. Normothymics may be assigned to essentially less part of the patients and 18% of them need nootropics that is consistent with routine practice.
authors.forename: V N
authors.initials: VN
authors.lastname: Kozyrev
authors.forename: A B
authors.initials: AB
authors.lastname: Smulevich
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Drobizhev
authors.forename: G K
authors.initials: GK
authors.lastname: Kraeva
authors.forename: M A
authors.initials: MA
authors.lastname: Kubrakov
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D002749:Chlorprothixene / Q000627:therapeutic use; D003006:Clopenthixol / Q000627:therapeutic use; D003625:Data Collection; D018492:Dopamine Antagonists / Q000627:therapeutic use; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D005475:Flupenthixol / Q000627:therapeutic use; D006778:Hospitals, Psychiatric; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009031:Moscow; D018697:Nootropic Agents / Q000627:therapeutic use; D000077152:Olanzapine; D017891:Pharmacoepidemiology; D010640:Phenothiazines / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D018967:Risperidone / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D013469:Sulpiride / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D002227:Carbazoles; D002749:Chlorprothixene; D003006:Clopenthixol; D018492:Dopamine Antagonists; D005473:Fluoxetine; D005475:Flupenthixol; D008803:Mianserin; D000078785:Mirtazapine; D008996:Monoamine Oxidase Inhibitors; D018697:Nootropic Agents; D000077152:Olanzapine; D010640:Phenothiazines; D011619:Psychotropic Drugs; D018967:Risperidone; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013469:Sulpiride; C009830:pirlindole